Overview
- First doses were administered on World AIDS Day, with Zambia and Eswatini launching the injection at public ceremonies.
- In South Africa, a Wits University research unit funded by Unitaid is overseeing early use, with a broader national rollout expected next year.
- Gilead Sciences committed to provide the drug at no profit for two million people over three years in high HIV‑burden countries.
- Unitaid and the Bill & Melinda Gates Foundation announced agreements enabling generics from 2027 at about $40 per year in more than 100 countries.
- Critics say the current pledge will not meet need and note the US list price of about $28,000 per person per year as a barrier to equitable access.